LOS ANGELES, CA - September 24, 2026 (NEWMEDIAWIRE) - VERAXA Biotech (NASDAQ: VRXA) is shifting its focus to advancing its oncology pipeline and implementing industrial partnerships for its technology ...

Curitiba-based biotechnology company advances synthesized compounds into in vitro testing in Brazilian laboratories.

Austin, Texas, October 7th, 2026, FinanceWireVERAXA Biotech (NASDAQ: VRXA), a developer of next-generation antibody-based ...

TAIPEI CITY, Taiwan, September 29, 2026--(BUSINESS WIRE)--Oneness Biotech Co., Ltd., a Taiwan-based biotechnology company advancing innovative drugs for metabolic disorders, today announced completion ...

Session: Advances in Oncology Panel Presenter: Walter Klemp, Chairman and Chief Executive Officer of Moleculin Date/time: Wednesday, October 14, 2026, from 9:00 - 10:00 a.m. ET Location: NYY Room at ...

Kiran Biotech is developing AvidinOX®, a protein-based platform designed to improve site-specific localization of biotinylated compounds. The technology enables covalent anchoring at targeted sites, ...

Oncolytics Biotech remains in focus as the cancer-focused biotech advances its oncolytic virus pelareorep through multiple clinical trials, including breast and gastrointestinal cancer studies, ...

A new biosensor developed at the Department of Energy's Oak Ridge National Laboratory detects the emerging presence of fungus on plants at the molecular level, paving the way for next-generation crop ...

Selected among 120 high-potential deep-tech startups representing India at Bharat Innovates 2026 in Nice, France ATGC Biotech Pvt. Ltd., an Indian deep-tech agricultural biotechnology company ...

TORONTO, March 26, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory ...

Austin, Texas, September 24th, 2026, FinanceWireVERAXA Biotech (NASDAQ: VRXA) is shifting its focus to advancing its ...

Oneness Biotech Co., Ltd., a Taiwan-based biotechnology company advancing innovative drugs for metabolic disorders, today announced completion of the single-ascending dose (SAD) portion (Part A) in ...